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Introduction
Chronic myelomonocytic leukemia (CMML) is a bone 
marrow disorder characterized by the overproduction 
of maturing monocytic cells, and sometimes dysplastic 
neutrophils. CMML is often accompanied by anemia and/
or thrombocytopenia (1). In 2006, the Food and Drug 
Administration approved decitabine for the treatment of 
CMML. The non-hematologic side effects of decitabine are 
minimal and myelosuppression-associated complications 
are acceptable. Here, we describe one patient with CMML 
who developed sudden hearing loss (SHL) under decitabine 
treatment. 
Case report
A 73-year-old male patient came to our hospital with knee pain 
for two weeks. During this hospitalization, he had leukocytosis, 
with a white blood cell (WBC) count of 36,280/mm3. 
The differential count showed 53% neutrophils, 3% 
lymphocytes, 25% monocytes, and 5% blasts. Coagulation 
studies revealed an activated partial thromboplastin time 
(aPTT) of 33.7 s and a prothrombin time (PT) of 13.3 s. 
The patient was transferred to the hematologist. CMML 
was diagnosed based on a bone marrow biopsy and aspiration 
(promonocytes, 7.4%; blasts, 4.4%). The patient was started 
on decitabine (20 mg/m2 for 5 d in a 4-week cycle). After 2 
cycles, the WBC count had declined to 14,110/mm3 and the 
other side effects were minimal. 
He was hospitalized for the 3rd cycle of decitabine 
and the laboratory testing showed a total leukocyte count 
of 22,520/mm3. During the 3rd cycle on the 5th day of 
chemotherapy, he abruptly complained of difficulty hearing 
on the left side without dizziness. The physical examination 
revealed normal external auditory canals with intact 
tympanic membranes bilaterally. Pure tone audiometry 
revealed moderate sensorineural hearing loss in the right 
ear (48 dB HL by 4-tone average) and severe sensorineural 
hearing loss in the left ear (84 dB HL by 4-tone average; 
Figure 1). Speech audiometry revealed word discrimination 
scores of 80% for the right ear and 20% for the left ear. 
Radiologic evaluation of the temporal region and brain, 
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including magnetic resonance imaging (MRI) scan, revealed 
no significant abnormalities of the brain and inner ear 
(Figure 2).
Even though there were no baseline audiologic test 
results before the onset of symptoms, the patient previously 
had equal hearing in both ears and the test results were 
compatible with sensorineural hearing loss in the left ear, 
thus the patient was diagnosed with SHL based on the 
history and audiologic testing. At the time of symptom 
onset, the WBC count was 32,600/mm3, the hemoglobin 
was 7.6 g/dL, and the platelet count was 339,000/mm3. 
Intratympanic steroids were injected every other day 
(six times) instead of oral steroids based on the patient’s 
hematologic status. Carbogen was also inhaled to increase 
the blood flow and oxygen supply to the injured hair cells 
of the cochlear and inner ear structures. The patient had 
follow-up visits and pure tone audiograms were conducted 
for eight months. During the eight months, treatment 
was continued to the 8th cycle of decitabine as planned. 
While a hematologic response was achieved, the WBC 
count normalized to 9,980/mm3, and pure tone audiometry 
persistently revealed a similar hearing threshold (49 dB HL 
in the right ear, 78 dB HL in the left ear by 4-tone average; 
Figure 3). Speech audiometry revealed word discrimination 
scores of 96% for the right ear and 32% for the left ear. 
Despite, hematologic improvement, hearing improvement 
was not achieved.
Discussion 
CMML is a hybrid disorder characterized by proliferation 
of the myeloid series and dysplasia of the erythroid-
megakaryocytic series (2). The incidence of CMML is 
approximately three cases per 100,000 individuals >60 years 
of age, and accounts for 12% of all French-American-British 
(FAB)-defined myelodysplastic syndrome (MDS). The 
clinical symptoms and other phenotypic manifestations are 
caused by complications resulting from cytopenia, dysplastic 
cells that function abnormally, leukemic infiltration of 
various organ systems, and general constitutional symptoms, 
such as fever and malaise (3). Otologic findings, such as, 
SHL, tinnitus, vertigo, facial weakness, and infection, 
were found in 16-40% of leukemic patients (4). However, 
SHL is a rare manifestation in CMML patients (4). The 
pathogenesis of hearing loss in chronic myeloid leukemia 
(CML) involves multiple mechanisms, such as leukemic 
infiltration, hyperviscosity syndrome, inner ear hemorrhage, 
and infection. Hyperleukocytosis results in a slowing of 
the circulation through the small blood vessels in the 
brain stem, and is thus as a cause of deafness (5). Cochlear 
damage is secondary to the anoxia or hypoxia generated 
and can occur due to permanent and/or temporary vessel 
occlusion by hyperviscosity, such as multiple myeloma and 
Waldenstrom's macroglobulinemia (6). Hyperviscosity 
syndrome often requires leukocyte counts >50,000/mm3.
In our case, there were intermittent normal WBC counts 
reflecting a hematologic response after decitabine treatment, 
but leukocytosis continued during the first three months of 
treatment, with a peak WBC count of 71,180/mm3. 
SHL is considered a syndrome, rather than a diagnosis, 
and is defined as hearing loss of at least 30 dB in 3 
sequential frequencies occurring over <3 d (7). There is no 
standard treatment protocol for SHL, but the most accepted 
treatment is a tapered course of oral systemic steroids.
Due to the side effects of high-dose systemic steroids, 
many physicians are hesitant to use systemic steroids 
for patients who have an underlying chronic disease. 
Intratympanic dexamethasone (ITD) offers the potential for 
direct delivery of high concentrations of the steroid to the 
inner ear, thus avoiding systemic effects (8).
We performed intratympanic steroid injection every 



























Figure 1 Pure tone audiogram obtained during the first 
examination. Audiogram shows moderate hearing loss in the right 
ear and severe hearing loss in the left ear. Bone conduction in high 
frequencies of the left ear was not tested.
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other day for a total of six times instead of oral steroid 
administration based on the patient’s hematologic status (9). 
Carbogen inhalation is known to cause vasodilation and 
increase blood flow and oxygen supply to injured hair cells 
of the cochlear and inner ear structures. We performed 
carbogen inhalation against the hyperviscosity theory.
Generally, in the case of sudden deafness, there is a 
reduced likelihood for hearing improvement after six months 
of symptom onset. The patient presented herein did not show 
a change in hearing level for eight months; we categorized 
his SHL as “no improvement” based on Siegel’s criteria.
One theory that explains the cause of SHL involves 
leukemia-mediated infarction of the inner and middle 
ears (10). A second theory suggests that hyperviscosity with 
occlusion of the labyrinthine and other small arteries of the 
vertebra-basilar area. A third theory focuses on the toxicities 
of decitabine, even if decitabine-related extramedullary 
toxicities are uncommon. There are few reports which have 
addressed ototoxicities of hypomethylating agents, such as 
decitabine. Indeed, there may be unknown adverse effects 
due to the short-term clinical experience (four years). There 
have been no reported cases of SHL in CMML patients 
treated with decitabine. We have described the first case 
of SHL in a patient with CMML while being treated with 
decitabine.
In conclusion, we must verify that idiopathic SHL can 
occur in CMML patients during treatment with decitabine. 
The theory that a poorly controlled underlying disease or 
decitabine can be associated with the causes of irreversible 
SHL has been confirmed. The patients being treated 
with decitabine need to be monitored for hearing loss and 
otologic symptoms.
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Figure 3 Audiogram obtained eight months after symptom onset. 
It shows no improvement of the thresholds as compared with 
Figure 1, and was not accompanied by subjective hearing gain. 
Figure 2 T2-weighted magnetic resonance imaging (MRI) scan shows no detectable abnormalities in the inner ear and auditory nerve. 
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